Long non‑coding RNA MKLN1‑AS aggravates hepatocellular carcinoma progression by functioning as a molecular sponge for miR‑654‑3p, thereby promoting hepatoma‑derived growth factor expression

Gao,Wanjun; Chen,Xiaohua; Chi,Wei; Xue,Ming

doi:10.3892/ijmm.2020.4722

Long non‑coding RNA MKLN1‑AS aggravates hepatocellular carcinoma progression by functioning as a molecular sponge for miR‑654‑3p, thereby promoting hepatoma‑derived growth factor expression

Authors:
- Wanjun Gao
- Xiaohua Chen
- Wei Chi
- Ming Xue
View Affiliations

Affiliations: Third Department of Cancer Clinical Medicine Center, Shibo High‑Tech Hospital, Zibo, Shandong 255086, P.R. China, Department of Oncology, PKUCare Luzhong Hospital, Zibo, Shandong 255400, P.R. China
Published online on: September 9, 2020 https://doi.org/10.3892/ijmm.2020.4722
Pages: 1743-1754
Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non‑coding RNAs (lncRNAs) have recently gained attention due to their important roles in human cancer types, such as breast and gastric cancer. The present study measured alterations in muskelin 1 antisense RNA (MKLN1‑AS) expression in hepatocellular carcinoma (HCC) and evaluated its clinical value in patients with HCC. Additionally, the current study investigated the effects of MKLN1‑AS on the malignant features of HCC cells. The detailed molecular mechanisms underlying the cancer‑promoting activities of MKLN1‑AS in HCC cells were also elucidated. MKLN1‑AS expression in HCC tissues and cell lines was detected using reverse‑transcription quantitative PCR (RT‑qPCR). Cell Counting Kit‑8 assays and flow cytometry were used to determine the roles of MKLN1‑AS in HCC cell proliferation and apoptosis. Migration and invasion assays, as well as tumor xenograft experiments were conducted to analyze migration and invasion in vitro and tumor growth in vivo, respectively. The interaction among microRNA‑654‑3p (miR‑654‑3p), MKLN1‑AS and hepatoma‑derived growth factor (HDGF) in HCC was investigated using luciferase reporter assay, RNA immunoprecipitation assay, RT‑qPCR, western blotting and rescue experiments. MKLN1‑AS was upregulated in HCC tissues and cell lines, and a high MKLN1‑AS expression was associated with shorter overall survival and disease‑free survival in patients with HCC. Functionally, the knockdown of MKLN1‑AS impaired HCC cell proliferation, migration and invasion, as well as induced cell apoptosis in vitro. Knockdown of MKLN1‑AS expression also inhibited cell proliferation in vivo. The results indicated that MKLN1‑AS functioned as a competing endogenous RNA by sponging miR‑654‑3p in HCC cells. Additionally, miR‑654‑3p targeting of HDGF was positively modulated by MKLN1‑AS, and miR‑654‑3p knockdown partially abrogated this effect. Rescue experiments demonstrated that knockdown of miR‑654‑3p and overexpression of HDGF both abolished MKLN1‑AS knockdown‑induced cellular processes in HCC. In summary, MKLN1‑AS induced pro‑oncogenic effects during HCC progression by serving as a molecular sponge for miR‑654‑3p to increase HDGF expression. Therefore, the MKLN1‑AS/miR‑654‑3p/HDGF axis may offer a novel target for the diagnosis, prognosis, prevention and treatment of HCC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
2	Goyal L, Qadan M and Zhu AX: Another treatment option for advanced hepatocellular carcinoma with portal vein thrombosis in China. JAMA Oncol. 5:938–939. 2019. View Article : Google Scholar : PubMed/NCBI
3	Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 46:765–781. 2010. View Article : Google Scholar : PubMed/NCBI
4	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
5	Medavaram S and Zhang Y: Emerging therapies in advanced hepatocellular carcinoma. Exp Hematol Oncol. 7:172018. View Article : Google Scholar : PubMed/NCBI
6	Ikeda K: Recent advances in medical management of hepatocellular carcinoma. Hepatol Res. 49:14–32. 2019. View Article : Google Scholar
7	Zhang Q, Wang S, Qiao R, Whittaker MR, Quinn JF, Davis TP and Li H: Recent advances in magnetic nanoparticle-based molecular probes for hepatocellular carcinoma diagnosis and therapy. Curr Pharm Des. 24:2432–2437. 2018. View Article : Google Scholar : PubMed/NCBI
8	Sartorius K, Makarova J, Sartorius B, An P, Winkler C, Chuturgoon A and Kramvis A: The regulatory role of microRNA in hepatitis-B virus-associated hepatocellular carcinoma (HBV-HCC) pathogenesis. Cells. 8:15042019. View Article : Google Scholar
9	Zakharia K, Luther CA, Alsabbak H and Roberts LR: Hepatocellular carcinoma: Epidemiology, pathogenesis and surveillance-implications for sub-Saharan Africa. S Afr Med J. 108:35–40. 2018.PubMed/NCBI
10	Hu G, Niu F, Humburg BA, Liao K, Bendi S, Callen S, Fox HS and Buch S: Molecular mechanisms of long noncoding RNAs and their role in disease pathogenesis. Oncotarget. 9:18648–18663. 2018. View Article : Google Scholar : PubMed/NCBI
11	Li Y, Egranov SD, Yang L and Lin C: Molecular mechanisms of long noncoding RNAs-mediated cancer metastasis. Genes Chromosomes Cancer. 58:200–207. 2019. View Article : Google Scholar
12	Liz J and Esteller M: lncRNAs and microRNAs with a role in cancer development. Biochim Biophys Acta. 1859:169–176. 2016. View Article : Google Scholar
13	Li W, He Y, Chen W, Man W, Fu Q, Tan H, Guo H, Zhou J and Yang P: Knockdown of LINC00467 contributed to Axitinib sensitivity in hepatocellular carcinoma through miR-509-3p/PDGFRA axis. Gene Ther. Mar 27–2020.Epub ahead of print. View Article : Google Scholar
14	Lu Z, Yu Y, Ding X, Jin D, Wang G, Zhou Y, Zhu Y, Na L, He Y and Wang Q: LncRNA FLJ33360 accelerates the metastasis in hepatocellular carcinoma by targeting miRNA-140/MMP9 axis. Am J Transl Res. 12:583–591. 2020.PubMed/NCBI
15	Liu C, Zhang M, Zhao J, Zhu X, Zhu L, Yan M, Zhang X and Zhang R: LncRNA FOXD3-AS1 mediates AKT pathway to promote growth and invasion in hepatocellular carcinoma through regulating RICTOR. Cancer Biother Radiopharm. 35:292–300. 2020. View Article : Google Scholar : PubMed/NCBI
16	Chen X, Tang FR, Arfuso F, Cai WQ, Ma Z, Yang J and Sethi G: The emerging role of long non-coding RNAs in the metastasis of hepatocellular carcinoma. Biomolecules. 10:662019. View Article : Google Scholar
17	Xu X, Tao Y, Shan L, Chen R, Jiang H, Qian Z, Cai F, Ma L and Yu Y: The role of microRNAs in hepatocellular carcinoma. J Cancer. 9:3557–3569. 2018. View Article : Google Scholar : PubMed/NCBI
18	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
19	Zhang T, Yang Z, Kusumanchi P, Han S and Liangpunsakul S: Critical role of microRNA-21 in the pathogenesis of liver diseases. Front Med (Lausanne). 7:72020. View Article : Google Scholar
20	Weidle UH, Schmid D, Birzele F and Brinkmann U: MicroRNAs involved in metastasis of hepatocellular carcinoma: Target candidates, functionality and efficacy in animal models and prognostic relevance. Cancer Genomics Proteomics. 17:1–21. 2020. View Article : Google Scholar :
21	Pratama MY, Pascut D, Massi MN and Tiribelli C: The role of microRNA in the resistance to treatment of hepatocellular carcinoma. Ann Transl Med. 7:5772019. View Article : Google Scholar : PubMed/NCBI
22	Li D, Wang T, Sun FF, Feng JQ, Peng JJ, Li H, Wang C, Wang D, Liu Y, Bai YD, et al: MicroRNA-375 represses tumor angiogenesis and reverses resistance to sorafenib in hepatocarcinoma. Cancer Gene Ther. July 3–2020.Epub ahead of print. View Article : Google Scholar
23	Xu Q and Liu K: MiR-369-3p inhibits tumorigenesis of hepatocellular carcinoma by binding to PAX6. J Biol Regul Homeost Agents. Jun 30–2020.Epub ahead of print.
24	Wang J, Li J, Chen L, Fan Z and Cheng J: MicroRNA-499 suppresses the growth of hepatocellular carcinoma by downregulating astrocyte elevated gene-1. Technol Cancer Res Treat. 19:15330338209202532020. View Article : Google Scholar : PubMed/NCBI
25	Song X, Cao G, Jing L, Lin S, Wang X, Zhang J, Wang M, Liu W and Lv C: Analysing the relationship between lncRNA and protein-coding gene and the role of lncRNA as ceRNA in pulmonary fibrosis. J Cell Mol Med. 18:991–1003. 2014. View Article : Google Scholar : PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
27	Shi SH, Jiang J, Zhang W, Sun L, Li XJ, Li C, Ge QD and Zhuang ZG: A novel lncRNA HOXC-AS3 acts as a miR-3922-5p sponge to promote breast cancer metastasis. Cancer Invest. 38:1–12. 2020. View Article : Google Scholar
28	Tian Y, Xia S, Ma M and Zuo Y: LINC00096 promotes the proliferation and invasion by sponging miR-383-5p and regulating RBM3 expression in triple-negative breast cancer. Onco Targets Ther. 12:10569–10578. 2019. View Article : Google Scholar : PubMed/NCBI
29	Yang GY, Zhang AQ, Wang J, Li CH, Wang XQ, Pan K, Zhou C and Dong JH: Hepatoma-derived growth factor promotes growth and metastasis of hepatocellular carcinoma cells. Cell Biochem Funct. 34:274–285. 2016. View Article : Google Scholar : PubMed/NCBI
30	Enomoto H, Nakamura H, Liu W, Iwata Y, Nishikawa H, Takata R, Yoh K, Hasegawa K, Ishii A, Takashima T, et al: Down-regulation of HDGF inhibits the growth of hepatocellular carcinoma cells in vitro and in vivo. Anticancer Res. 35:6475–6479. 2015.PubMed/NCBI
31	Enomoto H, Nakamura H, Liu W and Nishiguchi S: Hepatoma-derived growth factor: Its possible involvement in the progression of hepatocellular carcinoma. Int J Mol Sci. 16:14086–14097. 2015. View Article : Google Scholar : PubMed/NCBI
32	Agostini M, Ganini C, Candi E and Melino G: The role of noncoding RNAs in epithelial cancer. Cell Death Discov. 6:132020. View Article : Google Scholar : PubMed/NCBI
33	Tsagakis I, Douka K, Birds I and Aspden JL: Long non-coding RNAs in development and disease: Conservation to mechanisms. J Pathol. 250:480–495. 2020. View Article : Google Scholar : PubMed/NCBI
34	Wu Z, Wei ZH and Chen SH: LncUBE2R2-AS1 acts as a microRNA sponge of miR-302b to promote HCC progression via activation EGFR-PI3K-AKT signaling pathway. Cell Cycle. Aug 23–2020.Epub ahead of print. View Article : Google Scholar
35	Xie SC, Zhang JQ, Jiang XL, Hua YY, Xie SW, Qin YA and Yang YJ: LncRNA CRNDE facilitates epigenetic suppression of CELF2 and LATS2 to promote proliferation, migration and chemoresistance in hepatocellular carcinoma. Cell Death Dis. 11:6762020. View Article : Google Scholar : PubMed/NCBI
36	Li Y, Guo D, Lu G, Mohiuddin Chowdhury ATM, Zhang D, Ren M, Chen Y, Wang R and He S: LncRNA SNAI3-AS1 promotes PEG10-mediated proliferation and metastasis via decoying of miR-27a-3p and miR-34a-5p in hepatocellular carcinoma. Cell Death Dis. 11:6852020. View Article : Google Scholar : PubMed/NCBI
37	Shang R, Wang M, Dai B, Du J, Wang J, Liu Z, Qu S, Yang X, Liu J, Xia C, et al: Long noncoding RNA SLC2A1-AS1 regulates aerobic glycolysis and progression in hepatocellular carcinoma via inhibiting the STAT3/FOXM1/GLUT1 pathway. Mol Oncol. 14:1381–1396. 2020. View Article : Google Scholar : PubMed/NCBI
38	Chi Y, Gong Z, Xin H, Wang Z and Liu Z: Long noncoding RNA lncARSR promotes nonalcoholic fatty liver disease and hepatocellular carcinoma by promoting YAP1 and activating the IRS2/AKT pathway. J Transl Med. 18:1262020. View Article : Google Scholar : PubMed/NCBI
39	Mao LH, Chen SY, Li XQ, Xu F, Lei J, Wang QL, Luo LY, Cao HY, Ge X, Ran T, et al: LncRNA-LALR1 upregulates small nucleolar RNA SNORD72 to promote growth and invasion of hepatocellular carcinoma. Aging (Albany NY). 12:4527–4546. 2020. View Article : Google Scholar
40	Jin J, Xu H, Li W, Xu X, Liu H and Wei F: LINC00346 acts as a competing endogenous RNA regulating development of hepatocellular carcinoma via modulating CDK1/CCNB1 axis. Front Bioeng Biotechnol. 8:542020. View Article : Google Scholar : PubMed/NCBI
41	Chen S, Wang G, Tao K, Cai K, Wu K, Ye L, Bai J, Yin Y, Wang J, Shuai X, et al: Long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 cooperates with enhancer of zeste homolog 2 to promote hepatocellular carcinoma development by modulating the microRNA-22/Snail family transcriptional repressor 1 axis. Cancer Sci. 111:1582–1595. 2020. View Article : Google Scholar : PubMed/NCBI
42	Zhao JT, Chi BJ, Sun Y, Chi NN, Zhang XM, Sun JB, Chen Y and Xia Y: LINC00174 is an oncogenic lncRNA of hepatocellular carcinoma and regulates miR-320/S100A10 axis. Cell Biochem Funct. Mar 3–2020.Epub ahead of print.
43	Xiao JR, Wang K, Liu Y, Li ZW, Zhou YJ, Wang HZ, Lu JY, Cheng SS and Wei S: Exploring of a prognostic long non-coding RNA signature of hepatocellular carcinoma by using public database. Zhonghua Liu Xing Bing Xue Za Zhi. 40:805–809. 2019.In Chinese. PubMed/NCBI
44	Ma Y, Zhang J, Wen L and Lin A: Membrane-lipid associated lncRNA: A new regulator in cancer signaling. Cancer Lett. 419:27–29. 2018. View Article : Google Scholar : PubMed/NCBI
45	Niu ZS, Wang WH, Dong XN and Tian LM: Role of long noncoding RNA-mediated competing endogenous RNA regulatory network in hepatocellular carcinoma. World J Gastroenterol. 26:4240–4260. 2020. View Article : Google Scholar : PubMed/NCBI
46	Ye Y, Shen A and Liu A: Long non-coding RNA H19 and cancer: A competing endogenous RNA. Bull Cancer. 106:1152–1159. 2019. View Article : Google Scholar : PubMed/NCBI
47	Niu YC, Tong J, Shi XF and Zhang T: MicroRNA-654-3p enhances cisplatin sensitivity by targeting QPRT and inhibiting the PI3K/AKT signaling pathway in ovarian cancer cells. Exp Ther Med. 20:1467–1479. 2020. View Article : Google Scholar : PubMed/NCBI
48	Deng G, Mou T, He J, Chen D, Lv D, Liu H, Yu J, Wang S and Li G: Circular RNA circRHOBTB3 acts as a sponge for miR-654-3p inhibiting gastric cancer growth. J Exp Clin Cancer Res. 39:12020. View Article : Google Scholar : PubMed/NCBI
49	Geraldo MV, Nakaya HI and Kimura ET: Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer. Oncotarget. 8:9597–9607. 2017. View Article : Google Scholar :
50	Zhou X, Li J, Teng J, Liu Y, Zhang D, Liu L and Zhang W: Long noncoding RNA BSN-AS2 induced by E2F1 promotes spinal osteosarcoma progression by targeting miR-654-3p/SYTL2 axis. Cancer Cell Int. 20:1332020. View Article : Google Scholar : PubMed/NCBI
51	Yang J, Chen S, Dou W, Xie R and Gao J: miR-654-3p predicts the prognosis of hepatocellular carcinoma and inhibits the proliferation, migration, and invasion of cancer cells. Cancer Biomark. 28:73–79. 2020. View Article : Google Scholar : PubMed/NCBI
52	Huang JS, Chao CC, Su TL, Yeh SH, Chen DS, Chen CT, Chen PJ and Jou YS: Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma. Biochem Biophys Res Commun. 315:950–958. 2004. View Article : Google Scholar : PubMed/NCBI